Protein Kinase Structure, Function, and its Binding Sites for Understanding the Role in Anticancer Therapy
Abstract
Background:Protein kinases are involved in regulating different aspects of metabolism including cell growth, differentiation and regulation of cell cycle. Deregulated protein kinases are thought to affect various forms of tumor growth. The advent of protein kinase inhibitors has caused a great
shift in the way we treat cancer.
Purpose: There were several inhibitors of protein kinases that had been approved by the FDA in the last few decades. Therefore the need of the hour is to know the structure of the protein kinase to design the effective therapy for cancer treatment. Interaction of the drug with the protein is successful if the drug binds to the cavity of the receptor or protein and brings conformational changes, therefore the binding site in the protein should be well understood.
Conclusion: Thus in this mini review we have systematically discussed the structure of protein kinase and their binding sites so the future designing of the potential molecules should have better efficacy.
- Page Number : 79-84
- Keywords
Protein kinases, Binding sites, Cancer therapy - DOI Number
10.15415/jptrm.2020.82011 -
Authors
- Adarsh Sahu Department of Pharmaceutical Sciences, Dr Harisingh Gour University, Sagar, Madhya Pradesh - 470003, India
References
- Abramson, H. N. (2016). Kinase inhibitors as potential agents in the treatment of multiple myeloma. Oncotarget, 7(49), 81926-81968. https://doi.org/10.18632/oncotarget.10745
- Barr, G. D., & Piper, D. W. (1981). Possible ranitidine hepatitis. Medical Journal of Australia, 2(8), 421. https://doi.org/10.5694/j.1326-5377.1981. tb101036.x
- Berndt, A., et al. (2010). The p110δ structure: mechanisms for selectivity and potency of new PI3K inhibitors. Nature Chemical Biology, 6, 117–124. https://doi.org/10.1038/nchembio.293
- Bhullar, K. S., et al. (2018). Kinase-targeted cancer therapies: progress, challenges and future directions. Molecular Cancer, 17(1), 1-20. https://doi.org/10.1186/s12943-018-0804-2
- Botta, M. (2014). New frontiers in kinases: special issue, ACS Medicinal Chemistry Letters, 5(4), 270. https://doi.org/10.1021/ml500071m
- Cohen, P. (2000). The regulation of protein function by multisite phosphorylation — A 25 year update. Trends in Biochemical Sciences, 25(12), 596–60. https://doi.org/10.1016/s0968-0004(00)01712-6
- Dhuguru, J., & Skouta, R. (2020). Role of Indole Scaffolds as Pharmacophores in the Development of Anti-Lung Cancer Agents. Molecules, 25(7), 1615. https://doi.org/10.3390/molecules25071615
- Elmenier, F. M., Lasheen, D. S., & Abouzid, K. A., (2019). Phosphatidylinositol 3 kinase (PI3K) inhibitors as new weapon to combat cancer. European Journal of Medicinal Chemistry, 183(1), 111718. https://doi.org/10.1016/j.ejmech.2019.111718
- FDA grants fast track status to enzastaurin for newly diagnosed glioblastoma. (2020, July 17). Hematology/ Oncology. Retrieved from: https://www.healio.com/ news/hematology-oncology/20200717/fda-grants-fast-track-status-to-enzastaurin-for-newly-diagnosed-glioblastoma
- Ficarro, S. B., et al. (2002). Phosphoproteome analysis by mass spectrometry and its application to Saccharomyces cerevisiae. Nature Biotechnology, 20(3), 301–305. https://doi.org/10.1038/nbt0302-301
- Heath, C. M., Stahl, P. D., & Barbieri, M. A., (2003). Lipid kinases play crucial and multiple roles in membrane trafficking and signaling. Histol Histopathol, 18(3), 989-998. https://doi.org/10.14670/HH-18.989
- Hemmer, W., McGlone, M., Tsigelny, I., & Taylor, S. S. (1997). Role of the glycine triad in the ATP-binding site of cAMP-dependent protein kinase. Journal of Biological Chemistry, 272(27), 16946–16954. https://doi.org/10.1074/jbc.272.27.16946
- Huse, M., & Kuriyan, J. (2002). The conformational plasticity of protein kinases. Cell, 109(3), 275–282. https://doi.org/10.1016/s0092-8674(02)00741-9
- Kanev, G.K., et al. (2019). The landscape of atypical and eukaryotic protein kinases. Trends in Pharmacological Sciences, 40(11), 818-832. https://doi.org/10.1016/j. tips.2019.09.002
- Kornev, A. P., Taylor, S. S., & Eyck, L. F. T. (2008). A helix scaffold for the assembly of active protein kinases. Proceeding in National Academic Sciences USA, 105(38), 14377–14382. https://doi.org/10.1073/ pnas.0807988105
- Le Tourneau, C., Raymond, E., & Faivre, S. (2007). Sunitinib: A Novel Tyrosine Kinase Inhibitor. A Brief Review of Its Therapeutic Potential in the Treatment of Renal Carcinoma and Gastrointestinal Stromal Tumors (GIST). Therapeutic Clinical Risk Management, 3(2), 341–348. https://doi.org/10.2147/tcrm.2007.3.2.341
- Levinson, N. M., Kuchment, O., Shen, K., Young, M. A., & Koldobskiy, M. (2006). A Src-like inactive conformation in the abl tyrosine kinase domain. PLoS Biology, 4(5), e144. https://doi.org/10.1371/journal.pbio.0040144
- Manning, G., Whyte, D. B., Martinez, R., Hunter, T., & Sudarsanam, S. (2002). The protein kinase complement of the human genome. Science, 298(5600), 1912–1934. https://doi.org/10.1126/science.1075762
- Melnikova, I., & Golden, J. (2004). Targeting protein kinases. Nature Review Drug Discovery, 3, 993–994. https://doi.org/10.1038/nrd1600
- Motiwala, T., & Samson, T. J. (2006). Role of protein tyrosine phosphatases in cancer, Progress in Nucleic Acid Research and Molecular Biology, 81, 297-329. https://doi.org/10.1016/S0079-6603(06)81008-1
- Muller, S., Chaikuad, A., Gray, N. S., & Knapp, S. (2015). The ins and outs of selective kinase inhibitor development. Nature Chemical Biology, 11(11), 818–821. https://doi.org/10.1038/nchembio.1938
- Patterson, H., Nibbs, R., McInnes, I., & Siebert, S. (2014). Protein kinase inhibitors in the treatment of inflammatory and autoimmune diseases. Clinical & Experimental Immunology, 176(1), 1-10. https://doi.org/10.1111/cei.12248
- Scheeff, E. D., & Bourne, P. E. (2005). Structural evolution of the protein kinase-like superfamily. PLoS Computational Biology, 1(5), e49. https://doi.org/10.1371/journal.pcbi.0010049
- Shaw, A. S., Kornev, A. P., Hu, J., Ahuja, L. G., & Taylor S. S. (2014). Kinases and pseudokinases: Lessons from RAF. Molecular Cell Biology, 34(9), 1538–1546. https://doi.org/10.1128/MCB.00057-14
- Taylor, S. S., & Kornev, A. P., (2010). Protein kinases: Evolution of dynamic regulatory proteins. Trends in Biochemical Sciences, 36, 65–77. https://doi.org/10.1016/j.tibs.2010.09.006
- Taylor, S. S., et al. (2004). PKA: A portrait of protein kinase dynamics. Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics, 1697(1-2), 259–269. https://doi.org/10.1016/j.bbapap.2003.11.029
- Tomasini, P., et al. (2019). Alectinib in the Treatment of ALK-Positive Metastatic Non-Small Cell Lung Cancer: Clinical Trial Evidence and Experience with a Focus on Brain Metastases. Therapeutic Advances Respiratory Diseases, 13, 1753466619831906. https://doi.org/10.1177/1753466619831906
- U.S. Food & Drug Administration (2017). New drugs at FDA: CDER’s New Molecular Entities and New Therapeutic Biological Products. FDA. Retrieved from: https:// www.fda.gov/Drugs/DevelopmentApprovalProcess/ DrugInnovation/default.htm
- Vlahovic, G., & Crawford, J. (2003). Activation of tyrosine kinases in cancer. Oncologist, 8(6), 531–8. https://doi.org/10.1634/theoncologist.8-6-531
- Wu, P., Clausen, M. H., & Nielsen, T. E., (2015). Allosteric small-molecule kinase inhibitors. Pharmacology & Therapeutics, 156, 59–68. https://doi.org/10.1016/j.pharmthera.2015.10.002